JMP Securities Maintains Edwards Lifesciences Corp to Market Outperform with Price Target $130.00

Brokerage firm JMP Securities Maintains its rating on Edwards Lifesciences Corp(NYSE:EW). In a research note issued to the investors, the brokerage major Raises the price-target to $130.00 per share. The shares have been rated Market Outperform. The rating by JMP Securities was issued on Jul 28, 2016.

In a different note, On Jul 27, 2016, Bank of America said it Upgrades its rating on Edwards Lifesciences Corp. The shares have been rated ‘Buy’ by the firm. On Jul 27, 2016, Barclays said it Maintains its rating on Edwards Lifesciences Corp. In the research note, the firm Raises the price-target to $105.00 per share. The shares have been rated ‘Equalweight’ by the firm. On Jul 27, 2016, Citigroup said it Maintains its rating on Edwards Lifesciences Corp. In the research note, the firm Raises the price-target to $86.00 per share. The shares have been rated ‘Sell’ by the firm. On Jul 27, 2016, UBS said it Maintains its rating on Edwards Lifesciences Corp. In the research note, the firm Raises the price-target to $135.00 per share. The shares have been rated ‘Buy’ by the firm. On Jul 27, 2016, Morgan Stanley said it Maintains its rating on Edwards Lifesciences Corp. In the research note, the firm Raises the price-target to $110.00 per share. The shares have been rated ‘Overweight’ by the firm. On Jul 27, 2016, BTIG Research said it Maintains its rating on Edwards Lifesciences Corp. In the research note, the firm Raises the price-target to $122.00 per share. The shares have been rated ‘Buy’ by the firm.

Edwards Lifesciences Corp (EW) shares turned negative on Thursdays trading session with the shares closing down -0.38 points or -0.34% at a volume of 7,32,535. The pessimistic mood was evident in the company shares which never went considerably beyond the level of $113.99. The peak price level was also seen at $113.99 while the days lowest was $112.59. Finally the shares closed at $112.98. The 52-week high of the shares is $117.46 while the 52-week low is $62.53. According to the latest information available, the market cap of the company is $24,051 M.

Edwards Lifesciences Corp(EW) last announced its earnings results on Jul 26, 2016 for Fiscal Year 2016 and Q2.Company reported revenue of $759.30M. Analysts had an estimated revenue of $724.51M. Earnings per share were $0.76. Analysts had estimated an EPS of $0.70.

Several Insider Transactions has been reported to the SEC. On Jul 7, 2016, Huimin Wang (CVP, Japan & Intercontinental) sold 13,650 shares at $98.44 per share price.Also, On Jul 5, 2016, Larry L Wood (CVP, THV Replacement) sold 13,257 shares at $99.13 per share price.On Jun 9, 2016, Michael A Mussallem (Chairman & CEO) sold 49,100 shares at $102.25 per share price, according to the Form-4 filing with the securities and exchange commission.

Edwards Lifesciences Corporation is focused on technologies that treat structural heart disease and critically ill patients. The Company is engaged in the development and commercialization of heart valve therapies. It is a manufacturer of heart valve systems and repair products used to replace or repair a patient’s diseased or defective heart valve. The Company develops hemodynamic monitoring systems used to measure a patient’s cardiovascular function in the hospital setting. Patients in the hospital setting including high-risk patients in the operating room or intensive care unit are candidates for having their cardiac function or fluid levels monitored by the its Critical Care products. The Company’s products and technologies it offers to treat advanced cardiovascular disease are categorized into three main areas: Transcatheter Heart Valve Therapy Surgical Heart Valve Therapy and Critical Care.

Comments (0)

Leave a Reply

Your email address will not be published. Required fields are marked *